By blocking the Akt signaling pathway and increasing DNA breakage, the HDAC Class I inhibitor sNDX-275 can significantly promote Trastuzumab-induced growth inhibition in erbB2-overexpressed breast cancer cells, which may also overcome Trastuzumab resistance in breast cancer immunotherapy (129). Here, ERBB2 is linked to breast cancer.